Evidence map›Paper›PMID 28258538›Full record

ArticleDrugs & aging2017

Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.

Laia Calvó-Perxas, Oriol Turró-Garriga, Joan Vilalta-Franch, Manuela Lozano-Gallego, Rosa de Eugenio, Fabián Márquez, Olga Carmona, Jordi Gich, Anna Manzano, Marta Viñas and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drugs & aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. An update on the novel and approved drugs for Alzheimer disease.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Current and Future Treatments in Alzheimer Disease: An Update.Journal of central nervous system disease · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Laia Calvó-PerxasGirona Biomedical Research Institute (IdIBGI), C/Dr. Castany, s/n, Salt, 17190, Girona, Catalonia, Spain.
Oriol Turró-GarrigaGirona Biomedical Research Institute (IdIBGI), C/Dr. Castany, s/n, Salt, 17190, Girona, Catalonia, Spain.
Joan Vilalta-FranchGirona Biomedical Research Institute (IdIBGI), C/Dr. Castany, s/n, Salt, 17190, Girona, Catalonia, Spain.
Manuela Lozano-GallegoDementia Unit, Hospital de Santa Caterina, Salt, Catalonia, Spain.
Rosa de EugenioDementia Unit, Hospital de Palamós, Palamós, Catalonia, Spain.
Fabián MárquezNeurology Department, Hospital d'Olot, Olot, Catalonia, Spain.
Olga CarmonaNeurology Unit, Hospital de Figueres, Figueres, Catalonia, Spain.
Jordi GichNeurodegenerative Disease Unit, Hospital Universitari Dr. Josep Trueta, Girona, Catalonia, Spain.
Anna ManzanoNeurology Department, Hospital de Campdevànol, Campdevànol, Catalonia, Spain.
Marta ViñasGeriatrics and Neurology Department, Hospital de Blanes, Blanes, Catalonia, Spain.
Anna Mª RoigPharmacy Unit, Health Region of Girona, Girona, Catalonia, Spain.
Josep Garre-OlmoGirona Biomedical Research Institute (IdIBGI), C/Dr. Castany, s/n, Salt, 17190, Girona, Catalonia, Spain. josep.garre@ias.cat.
Registry of Dementias of Girona Study Group (ReDeGi Study Group)
Institut d'Investigació Biomèdica de Girona · ESUniversitat de Girona · ESManufacturas Serviplast (Spain) · ESCentre d'Estudis Avançats de Blanes · ESClínica Girona · ESHospital Santa Caterina · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitario De Cabueñes · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcetylcholinesterase inhibitors (AChEIs) and the N-methyl D-aspartate-antagonist memantine are indicated for the symptomatic treatment of Alzheimer's disease (AD).

objectivesOur aims were to describe the baseline characteristics of patients with AD according to prescription of these treatments after the diagnostic work-up to describe long-term trends in the use of these medications and to identify baseline characteristics associated with the frequency of use of each treatment.

methodsThis was a cohort study with a sample of 2992 patients with AD recorded in the Registry of Dementias of Girona (ReDeGi) between 2007 and 2014. Consumption of AChEIs and memantine was assessed using the Pharmacy Unit database from the Public Catalan Healthcare Service. We used generalized estimating equation analyses to identify the baseline characteristics associated with the consumption of AChEIs and memantine over time.

resultsMost of the patients (70.4%; 95% confidence interval [CI] 68.7-72.0) were prescribed antidementia medication at the time of diagnosis. Of these, 75.0% (95% CI 73.1-76.8) were prescribed AChEIs, 14.7% (95% CI 13.2-16.3) were prescribed an AChEI plus memantine, and 10.3% (95% CI 9.0-11.6) were prescribed memantine. Advanced age reduced the likelihood of AChEI consumption. Mild dementia severity increased the use of AChEIs, and moderate-advanced dementia increased the likelihood of memantine consumption. After diagnosis, the likelihood of AChEI consumption decreased from the first year until the fifth, whereas the likelihood of memantine consumption, either alone or in combination with AChEIs, increased.

conclusionsAntidementia drug use in this study showed the initial use of AChEIs alone with later use of AChEIs in combination with memantine and memantine alone in older patients with severe AD. Our findings are in agreement with current clinical practice guidelines for the pharmacological treatment of AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseCholinesterase InhibitorsCohort StudiesDrug UtilizationFemaleHumansMaleMemantineRegistriesSpainCholinesterase InhibitorsMemantine

Identifiers

PMID28258538
OpenAlexW2593022701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.